
Investments
90Portfolio Exits
12Funds
4About LYFE Capital
LYFE Capital operates as a life sciences investment firm. LYFE Capital provides capital to multi-stage companies that are primarily based throughout China and North America. The firm was founded in 2015 and is based in Jingan, Shanghai.

Want to inform investors similar to LYFE Capital about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest LYFE Capital News
Aug 25, 2023
Kyverna Therapeutics – a clinical-stage cell therapy company with the mission of engineering a new class of therapies for autoimmune diseases – recently announced the closing of an oversubscribed $60 million Series B financing round extension, bringing the total Series B financing round to $145 million. New investors Bain Capital Life Sciences and GordonMD Global Investments LP join existing investors Gilead Sciences, Westlake Village BioPartners, Vida Ventures, Northpond Ventures, RTW Investments, Insight Partners, CAM Capital, LYFE Capital, jVen Capital, and others. Chimeric antigen receptor (CAR) T-cell therapy involves modifying a patient’s immune T cells to recognize and remove B cells in the patient’s body. And Kyverna’s anti-CD19 CAR T-cell therapies, KYV-101 and KYV-201, specifically target CD19, a protein expressed on the surface of B cells involved in various types of autoimmune diseases, including lupus nephritis. These novel therapies have the potential to offer new hope to patients who have exhausted current treatment options. And Kyverna continues to explore additional indications for its anti-CD19 CAR T-cell therapies and develop a solid pipeline of promising immunotherapies to address unmet medical needs. KEY QUOTES: “We are pleased by the increasing investor confidence in the promise of Kyverna’s anti-CD19 CAR T-cell therapy for autoimmune diseases. This Series B extension will fund Kyverna’s clinical studies in the U.S. and Europe, enabling us to move more quickly toward bringing potentially transformative and life-saving therapies to patients. We continue to treat autoimmune patients in multiple indications and multiple geographies, and we look forward to sharing clinical data in the second half of 2023.” — Ryan Jones, chief financial officer of Kyverna “I have supported anti-CD19 CAR T-cell therapy for cancer since the early clinical trials. It is exciting to see Kyverna break into new frontiers by advancing cell therapies for autoimmune diseases. I am looking forward to future developments from Kyverna.” — Craig Gordon, M.D., founder, chief executive officer, and chief investment officer of Gordon MD Global Investments LP Trending on Pulse 2.0
LYFE Capital Investments
90 Investments
LYFE Capital has made 90 investments. Their latest investment was in HSCSCI as part of their Series B - II on August 8, 2023.

LYFE Capital Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
8/28/2023 | Series B - II | HSCSCI | $41.26M | No | 2 | |
8/3/2023 | Series B - II | Kyverna Therapeutics | $60M | No | 2 | |
4/19/2023 | Series B | Noah Medical | $150M | Yes | 1955 Capital, AME Cloud Ventures, Hillhouse Capital Management, HongShan, LYFE Capital, Prosperity7 Ventures, Shangbay Capital, SoftBank, Sunmed Capital, Tiger Global Management, Undisclosed Investors, and UpHonest Capital | 5 |
3/31/2023 | Series B | |||||
1/18/2023 | Series D |
Date | 8/28/2023 | 8/3/2023 | 4/19/2023 | 3/31/2023 | 1/18/2023 |
---|---|---|---|---|---|
Round | Series B - II | Series B - II | Series B | Series B | Series D |
Company | HSCSCI | Kyverna Therapeutics | Noah Medical | ||
Amount | $41.26M | $60M | $150M | ||
New? | No | No | Yes | ||
Co-Investors | 1955 Capital, AME Cloud Ventures, Hillhouse Capital Management, HongShan, LYFE Capital, Prosperity7 Ventures, Shangbay Capital, SoftBank, Sunmed Capital, Tiger Global Management, Undisclosed Investors, and UpHonest Capital | ||||
Sources | 2 | 2 | 5 |
LYFE Capital Portfolio Exits
12 Portfolio Exits
LYFE Capital has 12 portfolio exits. Their latest portfolio exit was ImmuneOnco on September 05, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
9/5/2023 | IPO | Public | 2 | ||
8/2/2022 | IPO | Public | 3 | ||
3/31/2022 | IPO | Public | 1 | ||
Date | 9/5/2023 | 8/2/2022 | 3/31/2022 | ||
---|---|---|---|---|---|
Exit | IPO | IPO | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | Public | Public | ||
Sources | 2 | 3 | 1 |
LYFE Capital Fund History
4 Fund Histories
LYFE Capital has 4 funds, including LYFE Capital Fund IV.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
4/22/2022 | LYFE Capital Fund IV | $935M | 1 | ||
10/11/2019 | LYFE Capital Fund III | ||||
5/30/2017 | LYFE Capital II | ||||
LYFE Capital Fund III (Phoenix) |
Closing Date | 4/22/2022 | 10/11/2019 | 5/30/2017 | |
---|---|---|---|---|
Fund | LYFE Capital Fund IV | LYFE Capital Fund III | LYFE Capital II | LYFE Capital Fund III (Phoenix) |
Fund Type | ||||
Status | ||||
Amount | $935M | |||
Sources | 1 |
LYFE Capital Team
7 Team Members
LYFE Capital has 7 team members, including current Founder, Managing Partner, James Zhao.
Name | Work History | Title | Status |
---|---|---|---|
James Zhao | Founder, Managing Partner | Current | |
Name | James Zhao | ||||
---|---|---|---|---|---|
Work History | |||||
Title | Founder, Managing Partner | ||||
Status | Current |